Weekly Investment Analysts’ Ratings Updates for Kura Oncology (KURA)

A number of firms have modified their ratings and price targets on shares of Kura Oncology (NASDAQ: KURA) recently:

• 2/6/2025 – Kura Oncology had its price target raised by analysts at Wedbush from $34.00 to $36.00. They now have an “outperform” rating on the stock.
• 2/6/2025 – Kura Oncology was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
• 2/6/2025 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $28.00 price target on the stock.
• 2/6/2025 – Kura Oncology had its price target raised by analysts at HC Wainwright from $37.00 to $40.00. They now have a “buy” rating on the stock.
• 1/8/2025 – Kura Oncology had its price target lowered by analysts at Scotiabank from $18.00 to $10.00. They now have a “sector perform” rating on the stock.

Kura Oncology Stock Performance

KURA stock opened at $8.28 on Tuesday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a twelve month low of $6.98 and a twelve month high of $24.17. The stock has a market capitalization of $643.85 million, a price-to-earnings ratio of -3.51 and a beta of 0.78. The firm’s fifty day simple moving average is $8.44 and its two-hundred day simple moving average is $14.43.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new stake in Kura Oncology in the third quarter worth about $25,000. Virtus ETF Advisers LLC lifted its position in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after buying an additional 3,061 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology during the third quarter valued at about $146,000. Harbor Advisors LLC purchased a new stake in shares of Kura Oncology during the fourth quarter valued at about $87,000. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Kura Oncology during the fourth quarter valued at about $90,000.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.